• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Management

Real World Data: COVID-19 Vaccination and Reduction in Risk for Reinfection

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Using real-world data, Cavanaugh et al. (CDC MMWR, 2021) assessed the association between vaccination and SARS-CoV-2 reinfection among persons previously infected with SARS-CoV-2

METHODS:

  • Case-control study
    • Residents of Kentucky
  • Participants
    • ≥18 years
    • Confirmed SARS-CoV-2 infection between March and December of 2020
  • Exposures
    • Reinfection status
      • Case patients: SARS-CoV-2 infection in 2020 and another positive test between May and June 2021
      • Control patients: SARS-CoV-2 infection in 2020 and no reinfection
    • Vaccination status
      • Fully vaccinated: first dose of J&J or second dose of Pfizer/Moderna was received ≥14 days before the reinfection date
      • Partially vaccinated: ≥1 dose of vaccine, but either the vaccination series was not completed or the final dose was received <14 days before the case-patient’s reinfection date
      • No vaccination
  • Matching of cases and controls
    • Based on age, sex, and date of initial infection

RESULTS:

  • Case-patients: 246 | Control patients: 492
    • 60.6% female, 82.9% of case patients initially infected October to December 2020
    • Case-patients full vaccinated: 20.3%
    • Control-patients fully vaccinated: 34.3%
  • Partial vaccination
    • Case-patients: 6.9%
    • Controls: 7.9%
  • Compared to patients with previous infections who were fully vaccinated, those with previous infections who were unvaccinated were 2.34 times more likely to experience reinfection
    • OR 2.34 (95% CI, 1.58 to 3.47)
  • Partial vaccination was not significantly associated with reinfection
    • OR 1.56 (95% CI, 0.81 to 3.01)

CONCLUSION:

  • In the real world, individuals with a history of SARS-CoV-2 infection that were unvaccinated were 2.34 times more likely to experience reinfection that those who were vaccinated
  • Lack of a significant association with partial vs full vaccination should be interpreted with caution | Statistical power limited due to small ‘n’ of individuals who were partially vaccinated
  • To reduce the risk of reinfection, everyone that is eligible for a COVID-19 vaccine should be offered one, even if they have previously been infected
  • The authors state

The findings from this study suggest that among previously infected persons, full vaccination is associated with reduced likelihood of reinfection, and, conversely, being unvaccinated is associated with higher likelihood of being reinfected

Learn More – Primary Sources:

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Does SARS-CoV-2 Infection Provide Protection Against Reinfection?
How Common is SARS-CoV-2 Reinfection among Healthcare Workers with Antibodies?
AstraZeneca and Pfizer Side Effects and Efficacy: Real World Data from the UK
COVID-19 mRNA Vaccine Effectiveness in the Real World Including in Those Partially Immunized

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site